Juno Therapeutics Inc.’s top investors will cash out stock worth hundreds of millions of dollars in the biotech company’s pending acquisition by Celgene Corp.
Celgene’s $9 billion takeover of Seattle-based Juno is priced at $87 per share.
Summit, New Jersey-based Celgene already owns $900.5 million worth of Juno stock.
Celgene bought about $850 million worth of Juno stock (at $93 per share) in 2015 and paid Juno $150 million in cash for options to develop and commercialize Juno’s immunotherapy…
Seattle Biz Journal
These Juno investors will cash out big in Celgene's billion takeover